Going back to class I: MHC and immunotherapies for childhood cancer

Kellie B. Haworth; Jennifer L. Leddon; Chun Yu Chen; Edwin M. Horwitz; Crystal L. Mackall; Timothy P. Cripe

doi:10.1002/pbc.25359

Going back to class I: MHC and immunotherapies for childhood cancer

Kellie B. Haworth, Jennifer L. Leddon, Chun Yu Chen, Edwin M. Horwitz, Crystal L. Mackall, Timothy P. Cripe

School of Medicine

Research output: Contribution to journal › Review article › peer-review

42 Scopus citations

Abstract

After decades of unfulfilled promise, immunotherapies for cancer have reached a tipping point, with several FDA approved products now on the market and many more showing promise in both adult and pediatric clinical trials. Tumor cell expression of MHC class I has emerged as a potential determinant of the therapeutic success of many immunotherapy approaches. Here we review current knowledge regarding MHC class I expression in pediatric cancers including a discussion of prognostic significance, the opposing influence of MHC on T-cell versus NK-mediated therapies, and strategies to reverse or circumvent MHC down-regulation.Pediatr Blood Cancer 2015;62:571-576.

Original language	English (US)
Pages (from-to)	571-576
Number of pages	6
Journal	Pediatric Blood and Cancer
Volume	62
Issue number	4
DOIs	https://doi.org/10.1002/pbc.25359
State	Published - Apr 1 2015

Keywords

Childhood cancers
Immunotherapy
MHC Class I

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Hematology
Oncology

Access to Document

10.1002/pbc.25359

Cite this

@article{0c49773c5e2e4c2d81df8d3db680fa59,

title = "Going back to class I: MHC and immunotherapies for childhood cancer",

abstract = "After decades of unfulfilled promise, immunotherapies for cancer have reached a tipping point, with several FDA approved products now on the market and many more showing promise in both adult and pediatric clinical trials. Tumor cell expression of MHC class I has emerged as a potential determinant of the therapeutic success of many immunotherapy approaches. Here we review current knowledge regarding MHC class I expression in pediatric cancers including a discussion of prognostic significance, the opposing influence of MHC on T-cell versus NK-mediated therapies, and strategies to reverse or circumvent MHC down-regulation.Pediatr Blood Cancer 2015;62:571-576.",

keywords = "Childhood cancers, Immunotherapy, MHC Class I",

author = "Haworth, {Kellie B.} and Leddon, {Jennifer L.} and Chen, {Chun Yu} and Horwitz, {Edwin M.} and Mackall, {Crystal L.} and Cripe, {Timothy P.}",

note = "Publisher Copyright: {\textcopyright} 2014 The Authors. Pediatric Blood & Cancer published by Wiley Periodicals, Inc.",

year = "2015",

month = apr,

day = "1",

doi = "10.1002/pbc.25359",

language = "English (US)",

volume = "62",

pages = "571--576",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "4",

}

TY - JOUR

T1 - Going back to class I

T2 - MHC and immunotherapies for childhood cancer

AU - Haworth, Kellie B.

AU - Leddon, Jennifer L.

AU - Chen, Chun Yu

AU - Horwitz, Edwin M.

AU - Mackall, Crystal L.

AU - Cripe, Timothy P.

PY - 2015/4/1

Y1 - 2015/4/1

N2 - After decades of unfulfilled promise, immunotherapies for cancer have reached a tipping point, with several FDA approved products now on the market and many more showing promise in both adult and pediatric clinical trials. Tumor cell expression of MHC class I has emerged as a potential determinant of the therapeutic success of many immunotherapy approaches. Here we review current knowledge regarding MHC class I expression in pediatric cancers including a discussion of prognostic significance, the opposing influence of MHC on T-cell versus NK-mediated therapies, and strategies to reverse or circumvent MHC down-regulation.Pediatr Blood Cancer 2015;62:571-576.

AB - After decades of unfulfilled promise, immunotherapies for cancer have reached a tipping point, with several FDA approved products now on the market and many more showing promise in both adult and pediatric clinical trials. Tumor cell expression of MHC class I has emerged as a potential determinant of the therapeutic success of many immunotherapy approaches. Here we review current knowledge regarding MHC class I expression in pediatric cancers including a discussion of prognostic significance, the opposing influence of MHC on T-cell versus NK-mediated therapies, and strategies to reverse or circumvent MHC down-regulation.Pediatr Blood Cancer 2015;62:571-576.

KW - Childhood cancers

KW - Immunotherapy

KW - MHC Class I

UR - http://www.scopus.com/inward/record.url?scp=84923250283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923250283&partnerID=8YFLogxK

U2 - 10.1002/pbc.25359

DO - 10.1002/pbc.25359

M3 - Review article

C2 - 25524394

AN - SCOPUS:84923250283

SN - 1545-5009

VL - 62

SP - 571

EP - 576

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 4

ER -

Going back to class I: MHC and immunotherapies for childhood cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this